Can ensidipine cure leukemia?

Enasidenib , as a therapeutic drug for acute myeloid leukemia (AML) caused by specific gene mutations (such asIDH2 mutations), has shown certain clinical efficacy.

Judging from current clinical research data, ensidipine has indeed achieved significant results in the treatment of adult patients with relapsed or refractory acute myeloid leukemia with specific genetic mutations. For example, in a clinical trial, the overall response rate of ensidipine reached approximately 40% for 199 AML patients with IDH2 mutations, of which the complete remission rate was close to 20%. These data strongly support the effectiveness of ensidipine in treating patients with this type of leukemia.

However, it needs to be clear that “cure” and “remission” are two different concepts. Although ensidipine can help some patients achieve complete remission, this does not mean that the leukemia has been completely cured. Because leukemia is a complex blood system disease whose pathogenesis involves abnormalities in multiple genes and signaling pathways, targeted therapy with a single drug is often difficult to achieve a radical cure.

In addition, ensidipine also has certain side effects and risks during treatment. Common side effects include nausea, vomiting, diarrhea, increased bilirubin levels, etc. These symptoms may have a certain impact on the patient's quality of life. At the same time, ensidipine may also cause serious adverse reactions such as differentiation syndrome, which requires close monitoring and timely treatment.

In summary, ensidipine has indeed shown significant clinical efficacy in the treatment of AML patients with specific genetic mutationsBut it cannot yet be concluded that it can completely cure leukemia. When patients choose to use ensidipine for treatment, they should fully understand its efficacy and possible risks, and carry out standardized treatment under the guidance of a doctor.